Annual General Meeting Statement

Summary by AI BETAClose X

Proteome Sciences plc reported at its Annual General Meeting that its services business is experiencing good order levels and a recovery in TMT and reagent sales in the first half of the year, following budget cuts in 2025. The company believes its significant investment over the past two years positions it well to achieve substantial returns in the growing proteomics field.

Disclaimer*

Proteome Sciences PLC
14 May 2026
 

 

14 May 2026

Proteome Sciences plc

("Proteome Sciences" or the "Company")

 

Annual General Meeting Statement

 

At the Company's Annual General Meeting ("AGM") being held today at 12.00 noon, the Chairman, Christopher Pearce, made the following statement:

 

"Good progress is being made in order levels in our services business and the recovery that we hoped for in TMT and reagent sales continues in the first half following the cuts in US NIH budgets and academic grants in 2025.

With the significant investment made in the business over the last 2 years, we believe we are well positioned to deliver substantial returns from our activities in the fast growing field of proteomics."

- Ends -

For further information:

Proteome Sciences plc

Christopher Pearce, Executive Chairman

Dr. Ian Pike, Chief Scientific Officer

Tel: +44 (0)20 7043 2116

Richard Dennis, Chief Commercial Officer

 



SP Angel Corporate Finance LLP  (Nominated Adviser & Broker) 


David Hignell/Richard Morrison/Josh Ray  (Corporate Finance)

Vadim Alexandre (Corporate Broking)

 

Tel: +44 (0) 20 3470 0470

 

 

About Proteome Sciences plc. (www.proteomics.com)

 

Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, with analysis using a range of depletion strategies in combination with TMTcalibrator™ providing access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Chemoproteomics using Solvent Shift  reveals the selectivity that drugs have to binding one or more proteins in the sample proteome.  Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.

Further information on the Company can be found on its website at: https://www.proteomics.com/

The Company's LEI is 213800Q62ICXANKU2986.

This announcement should be read in its entirety. In particular, the information in the "Important Notices" section of the announcement should be read and understood.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 

Companies

Proteome Sciences (PRM)
UK 100
FTSE quotes by TradingView

Latest directors dealings

All directors dealings today